Modified AAV8 Capsid for Retinal Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant Adeno-Associated Virus (rAAV) vectors have limitations in efficiently transducing a wide variety of retinal cell types, particularly bipolar cells, which are crucial for optogenetic therapies aimed at restoring vision in retinal degenerative diseases.
Innovation Solution
Development of recombinant AAV capsid proteins with mutations in specific regions, such as aa 587-595, to enhance transduction efficiency and specificity towards ocular cells, including bipolar cells, by altering the capsid protein sequence and using chimeric capsids to improve tissue tropism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild type AAV8 capsid is used, then transduction efficiency for RPE cells is high, but transduction efficiency for bipolar cells is low
Solution Approach 1:
The patent applies local quality by introducing specific amino acid mutations at positions 587-595 in the capsid protein sequence, which corresponds to the HI loop region. This localized modification changes the binding properties of the capsid to specifically enhance affinity for bipolar cell receptors while maintaining overall capsid structure and function, thereby achieving cell-type-specific transduction enhancement without compromising general viral integrity
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid sequence at positions 587-595 to optimize transduction efficiency. Through screening different mutant variants, the patent identifies specific sequence modifications that alter the capsid's physical-chemical properties, enabling enhanced binding to bipolar cells while reducing off-target transduction in other cell types
2Manufacturing precision
If capsid protein sequence is mutated to target bipolar cells, then transduction specificity for bipolar cells improves, but transduction efficiency for other ocular cells may decrease
Solution Approach 1:
The patent maintains overall transduction efficiency while improving bipolar cell specificity by introducing mutations only in the HI loop region (positions 587-595) of the capsid protein. This localized modification preserves the essential structural and functional domains of the capsid that are responsible for general cellular entry, while specifically altering the binding interface to preferentially recognize bipolar cell surface markers
Solution Approach 2:
The patent uses partial action by introducing limited amino acid substitutions rather than comprehensive capsid redesign. This approach modifies only the critical binding region to achieve enhanced bipolar cell targeting, while leaving the majority of the capsid structure unchanged to maintain broad ocular cell transduction capability
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.